Liang, Linda A.
Tanaka, Luana F.
Radde, Kathrin
Bussas, Ulrike
Ikenberg, Hans
Heideman, Daniëlle A. M.
Meijer, Chris J. L. M.
Blettner, Maria
Klug, Stefanie J.
Funding for this research was provided by:
Technische Universität München
Article History
Received: 14 December 2023
Accepted: 28 August 2024
First Online: 19 September 2024
Declarations
:
: Informed consent to participate in the MARZY prospective cohort study was provided by all study participants prior to screening at study baseline. The MARZY study was approved by the ethical committee of the state of Rhineland-Palatinate (Landesärztekammer Rheinland-Pfalz: 837.438.03 (4100)) and the state government data protection office. All recruitment, data collection and analyses were performed in accordance to Good Epidemiological Practice guidelines and the Declaration of Helsinki.
: Not Applicable.
: LAL, LFT, KR, UB, MB, and SJK declare no conflict of interest. DAMH and CJLMM are minority shareholders of Self-screen B.V., a spin-off company of Amsterdam UMC, location VUmc, which develops, manufactures, and licenses high-risk HPV and methylation marker assays for cervical cancer screening and holds patents on these tests. CJLMM is part-time CEO of Self-screen B.V., and has a very small number of shares of MDXHealth and previously QIAGEN, has received speaker’s fees from GSK, QIAGEN and SPMSD/Merck, and served occasionally on the scientific advisory boards of these companies. HI has received contributions for speaking engagements and travels as well as support for research projects from B&D, Hologic, Otto Bock, Qiagen and Roche Diagnostics during the last three years. HI is a shareholder in a laboratory that carries out conventional cytology, liquid-based cytology and molecular diagnostics.